New Enterprise Associates 17, L.P. — Form SCHEDULE 13D/A
Filed July 6, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
New Enterprise Associates 17, L.P. and related entities filed a joint Schedule 13D/A on July 6, 2026, disclosing an open market sale of 11,830 shares of Monte Rosa Therapeutics, Inc. by NEA Investment Holdings CF, LLC on July 2, 2026, at a weighted average price of $24.18 per share (range: $23.70–$24.68). The filing reflects a routine disclosure of insider transactions within the past 60 days.
Why this rating
Routine insider transaction filing with no material context change. Sale size and price unremarkable relative to typical VC fund activity; no control shift or strategic implication evident.
See more from July 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.